Hematopoietic stem cell targeted delivery method and system based on CART technology

Through genetic engineering technology, targeted transformation of CART cells and combined with nanocarrier systems, the problem of low recognition and delivery efficiency of CART cells is solved, and efficient targeted delivery and safety improvement of hematopoietic stem cells is achieved, providing hematopoietic stem cell transplantation treatment New technical means.

CN118956764AInactive Publication Date: 2024-11-15TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411030027.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing CART cells lack the specific recognition ability of hematopoietic stem cells, have low delivery efficiency, poor system stability and biocompatibility, and lack effective in vivo tracking and monitoring technology, resulting in insufficient anti-tumor effects and significant side effects.

Method used

CART cells are targeted and modified through genetic engineering technology, so that their surface expression specifically recognizes receptor proteins, combines nanocarriers or microsphere systems to improve stability and delivery efficiency, select biocompatible materials and introduce fluorescence or magnetic resonance imaging Technology conducts real-time monitoring.

Benefits of technology

Accurate targeted recognition and efficient delivery of CART cells is achieved, the therapeutic effect is improved, the stability and safety in the body are enhanced, and the real-time evaluation of the delivery path and targeting effect is provided, reducing side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956764A_ABST
    Figure CN118956764A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of biological medicine, and discloses a CART technology-based hematopoietic stem cell targeted delivery method and system, the method comprises the following steps: CART cell targeted modification: CART cells are modified through a genetic engineering technology, so that the surface of the CART cells expresses receptor protein for specifically recognizing hematopoietic stem cells, and targeted recognition is realized; according to the optimized design of the conveying system, a nano-carrier or microsphere system is developed, and the modified CART cells are loaded in the nano-carrier or microsphere system, so that the stability and the conveying efficiency of the CART cells in blood are improved; due to the selection of a biocompatible material, the material with good biocompatibility is used as a carrier, so that the immunoreaction cannot be caused in vivo, and the material can be safely degraded after a conveying task is completed; in-vivo tracking and monitoring are carried out, fluorescence or magnetic resonance imaging and other technologies are introduced, and the conveying path and the targeting effect of the CART cells are monitored and evaluated in real time. According to the invention, the targeted recognition and conveying efficiency of the CART cells is obviously improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to but is not limited to the field of biomedical technology, and in particular relates to a hematopoietic stem cell targeted delivery method and system based on CART technology. Background Art

[0002] Chimeric Antigen Receptor-T cell (CAR-T) is a genetically modified

[0003] After modification, it can recognize specific target antigens in an MHC non-restrictive manner and continuously activate and expand T cells. The 2012 International Society of Cell Therapy Annual Meeting pointed out that biological immune cell therapy has become the fourth means of treating tumors in addition to surgery, radiotherapy, and chemotherapy, and will become an essential means of tumor treatment in the future. CAR-T cell infusion therapy is the most clear and effective form of immunotherapy in current tumor treatment. A large number of studies have shown that CAR-T cells can effectively recognize tumor antigens, induce specific anti-tumor immune responses, and significantly improve the survival of patients.

[0004] The targeted delivery method of hematopoietic stem cells based on CART technology faces the following problems:

[0005] Targeting issue: How to ensure that CART cells can accurately identify and target specific hematopoietic stem cells.

[0006] Delivery efficiency: How to improve the delivery efficiency of CART cells to ensure that they can stably and efficiently deliver hematopoietic stem cells to the target site in the body.

[0007] Biocompatibility and safety: Ensure that CART cells are harmless to the human body during and after delivery, and can be safely degraded or metabolized in the body.

[0008] In view of the above analysis, the technical problems that need to be solved urgently in the prior art are:

[0009] (1) Traditional CART cells lack the ability to specifically recognize hematopoietic stem cells, resulting in low efficiency of targeted delivery;

[0010] (2) The existing delivery systems have poor stability and biocompatibility, making it difficult to maintain activity in the blood for a long time;

[0011] (3) The lack of effective in vivo tracking and monitoring technology makes it impossible to evaluate the delivery pathway and targeting effect of CART cells in real time;

[0012] (4) The existing technology also has significant deficiencies in improving anti-tumor effects and reducing side effects. Summary of the invention

[0013] In response to the problems existing in the prior art, the present invention provides a method and system for targeted delivery of hematopoietic stem cells based on CART technology.

[0014] The present invention is implemented as follows: an intelligent system for targeted delivery of hematopoietic stem cells based on CART technology, comprising:

[0015] The targeted modification module is used to modify CART cells through genetic engineering technology so that they express receptor proteins that specifically recognize hematopoietic stem cells on their surface to achieve targeted recognition. It includes the following submodules:

[0016] The target recognition receptor determination submodule is used to determine the receptor proteins specifically expressed on the surface of hematopoietic stem cells;

[0017] Genetic engineering tool selection submodule, used to genetically modify CART cells using gene editing tools such as CRISPR / Cas9, TALENs or ZFN;

[0018] The vector construction submodule is used to construct expression vectors containing targeted receptor genes, such as adenovirus vectors, lentivirus vectors, etc.;

[0019] A gene transfection submodule is used to introduce the target receptor gene into CART cells through methods such as viral transfection, liposome transfection or electroporation;

[0020] The screening and verification submodule is used to screen the transfected CART cells through flow cytometry, fluorescence microscopy and other means to verify whether they successfully express specific receptor proteins;

[0021] The delivery system optimization design module is used to develop a nanocarrier or microsphere system to load the modified CART cells to improve their stability and delivery efficiency in the blood;

[0022] A biocompatible material selection module is used to select materials with good biocompatibility as carriers to ensure that they will not cause immune responses in the body and can be safely degraded after completing the delivery task;

[0023] In vivo tracking and monitoring module, which is used to introduce technologies such as fluorescence or magnetic resonance imaging to monitor and evaluate the delivery path and targeting effect of CART cells in real time;

[0024] The data analysis and feedback module is used to comprehensively analyze the in vivo tracking and monitoring data, evaluate the targeting effect of CART cells, and optimize the targeting modification and delivery system design based on the analysis results.

[0025] Through the above-mentioned intelligent system, the present invention can achieve precise targeted transformation and efficient delivery of CART cells, ensure their stability and targeted recognition ability in the body, and improve the therapeutic effect of hematopoietic stem cell transplantation.

[0026] The present invention provides a method for targeted delivery of hematopoietic stem cells based on CART technology, which specifically includes:

[0027] S1: Targeted modification of CART cells. Through genetic engineering technology, CART cells are modified to express receptor proteins on their surface that specifically recognize hematopoietic stem cells, thereby achieving targeted recognition;

[0028] S2: Optimize the design of the delivery system and develop a nanocarrier or microsphere system to load the modified CART cells to improve their stability and delivery efficiency in the blood;

[0029] S3: Selection of biocompatible materials: Use materials with good biocompatibility as carriers to ensure that they do not cause immune responses in the body and can be safely degraded after completing the delivery task;

[0030] S4: In vivo tracking and monitoring, introducing technologies such as fluorescence or magnetic resonance imaging to monitor and evaluate the delivery path and targeting effect of CART cells in real time.

[0031] Further, the S1 comprises the following steps:

[0032] (1) Determination of target recognition receptors: First, determine the receptor proteins specifically expressed on the surface of hematopoietic stem cells. These receptors can be designed for targeted modification of CART cells;

[0033] (2) Selection of genetic engineering tools: Genetic modification of CART cells using gene editing tools such as CRISPR / Cas9, TALENs or ZFN;

[0034] (3) Vector construction: construct an expression vector containing the target receptor gene, such as adenovirus vector, lentivirus vector, etc.;

[0035] (4) Gene transfection: The target receptor gene is introduced into CART cells through methods such as viral transfection, liposome transfection or electroporation;

[0036] (5) Screening and verification: The transfected CART cells are screened by flow cytometry, fluorescence microscopy, and other methods to verify whether they successfully express specific receptor proteins.

[0037] Further, the S2 comprises the following steps:

[0038] (1) Selection of nanocarriers: Select appropriate nanocarriers, such as liposomes, polymer nanoparticles, gold nanoparticles, etc. These carriers need to have good biocompatibility and stability;

[0039] (2) Preparation of nanocarriers: Prepare nanocarriers by emulsification-solvent evaporation, coprecipitation or ultrasound, and load the modified CART cells into them;

[0040] (3) Surface modification: The surface of the nanocarrier is modified to enable it to have the functions of targeted recognition and long circulation. For example, surface modification with polyethylene glycol (PEG) can prolong its circulation time in the blood.

[0041] (4) Binding of carrier and CART cells: CART cells are fixed on the nanocarrier through physical adsorption or chemical bonding to form a stable complex;

[0042] (5) Stability test: The stability and delivery efficiency of the nanocarrier-CART cell complex were tested through in vitro and in vivo experiments.

[0043] Further, the S3 comprises the following steps:

[0044] (1) Material screening: Select materials with good biocompatibility, such as polylactic-co-glycolic acid (PLGA), chitosan, hyaluronic acid, etc. These materials need to be FDA-certified to ensure their safety in the body;

[0045] (2) Material preparation: Based on the characteristics of the selected material, the corresponding method is used for preparation, such as solvent evaporation method, freeze drying method, etc.;

[0046] (3) Biocompatibility testing: Verify the biocompatibility and degradability of the material through in vitro cytotoxicity experiments, in vivo biodegradation experiments, etc., to ensure that it can be safely metabolized or degraded in the body after completing the delivery task;

[0047] (4) Functional modification: introducing functional groups, such as antibodies and peptides, into the material to enhance its targeting and stability.

[0048] Further, the S4 comprises the following steps:

[0049] (1) Selection of markers: Select markers suitable for in vivo imaging, such as fluorescent dyes (FITC, Rhodamine), magnetic nanoparticles (Fe3O4), etc.

[0050] (2) Binding of markers: The markers are bound to CART cells or nanocarriers by covalent bonding or physical adsorption to ensure that the markers do not fall off during delivery;

[0051] (3) Application of imaging technology: Fluorescence imaging, magnetic resonance imaging (MRI) and other technologies are used to track and monitor labeled CART cells in vivo;

[0052] (4) Data analysis: Analyze imaging data using image processing software to evaluate the delivery pathway, targeting efficiency, and retention time of CART cells at the target site;

[0053] (5) Feedback and optimization: Based on the monitoring results, adjustments and optimizations are made to the transformation of CART cells and the design of nanocarriers to further improve their targeted delivery effects.

[0054] Another object of the present invention is to provide a hematopoietic stem cell targeted delivery system based on CART technology, comprising:

[0055] Targeted transformation module, used to transform CART cells;

[0056] A carrier design module is used to develop nanocarrier or microsphere systems and load the modified CART cells into them;

[0057] The tracking and detection module uses fluorescence or magnetic resonance imaging technology to achieve in vivo tracking and monitoring of CART cells.

[0058] In combination with the above technical solutions and the technical problems solved, the advantages and positive effects of the technical solutions to be protected by the present invention are as follows:

[0059] First, improving targeting and delivery efficiency: Through genetic modification and the application of nanocarriers, the present invention enables CART cells to efficiently and accurately identify and target hematopoietic stem cells, thereby improving the therapeutic effect.

[0060] Improved safety and biocompatibility: The present invention uses biocompatible materials and real-time monitoring technology to ensure that CART cells are harmless to the human body during and after delivery, thereby improving the safety of patients.

[0061] Promoting the success rate of hematopoietic stem cell transplantation: The present invention improves the targeted delivery efficiency of hematopoietic stem cells, enhances their survival rate and function in the body, and promotes the success of transplantation treatment.

[0062] In summary, the present invention significantly improves the targeted recognition and delivery efficiency of CART cells. The modified CART cells can efficiently identify and target the target site where hematopoietic stem cells are located, greatly improving the therapeutic effect. The application of the nanocarrier system enhances the stability and biocompatibility of CART cells in the blood and prolongs their effective action time in vivo. The introduction of in vivo tracking and monitoring technology ensures real-time evaluation of the delivery path and targeting effect of CART cells, providing strong support for optimizing treatment plans.

[0063] Second, the technical solution of the present invention solves the technical problems that people have been eager to solve but have never been able to solve successfully:

[0064] The present invention has made significant technological progress in CART cell targeted delivery systems. Through the combination of genetic modification and nanocarriers, efficient and accurate targeted delivery is achieved, overcoming the limitations of traditional technologies. The design of multi-level immune regulation and personalized treatment plans improves the anti-tumor effect, reduces side effects, and significantly improves the safety and effectiveness of clinical treatment. The present invention not only provides new technical means for hematopoietic stem cell transplantation treatment, but also opens up a new direction for future tumor immunotherapy.

[0065] Third, the present invention solves several key problems in the prior art, especially in the targeted delivery and sustained activation maintenance of CART cells after hematopoietic stem cell transplantation. Traditional CART cell therapy faces problems such as short in vivo activity maintenance time, low targeted delivery efficiency, and easy clearance by the host immune system, which seriously limit the clinical application effect of CART cell therapy. In addition, traditional methods also have technical bottlenecks in the collaborative work of CART cells and hematopoietic stem cells and their real-time monitoring in vivo, and cannot ensure the safety and effectiveness of the treatment process.

[0066] The present invention integrates multiple technologies such as targeted transformation, delivery system optimization design, biocompatible material selection, and in vivo tracking and monitoring by introducing an intelligent system, which significantly improves the stability and targeted recognition ability of CART cells after transplantation. Through genetic engineering technology, CART cells are targeted and transformed so that their surface expression specifically recognizes receptor proteins for hematopoietic stem cells, achieving precise targeted recognition. At the same time, nanocarriers and microsphere systems have been developed to load the modified CART cells into them, thereby improving their stability and delivery efficiency in the blood, thereby ensuring the durability and stability of the therapeutic effect.

[0067] The present invention also selects materials with good biocompatibility as carriers to ensure that they do not cause immune responses in the body and can be safely degraded after completing the delivery task. This strategy effectively prevents CART cells from being recognized and cleared by the host immune system, reducing the risk of immune rejection. In addition, by introducing technologies such as fluorescence and magnetic resonance imaging, the delivery path and targeting effect of CART cells are monitored in real time, providing accurate imaging data and real-time feedback, further optimizing the treatment plan, and improving the safety and effectiveness of treatment.

[0068] The present invention has made significant technological progress in the targeted delivery and sustained activation maintenance of CART cells after hematopoietic stem cell transplantation. It not only solves the problem of persistence of CART cell activation, but also enhances the synergy of CART cells and hematopoietic stem cells by optimizing targeted transformation and delivery system design, and solves the problems of immune escape and tolerance. By introducing an intelligent system, the present invention realizes accurate monitoring and dynamic adjustment of the treatment process, significantly improves the treatment effect and patient prognosis, and provides strong technical support for clinical applications. BRIEF DESCRIPTION OF THE DRAWINGS

[0069] Figure 1 This is a flow chart of a method for targeted delivery of hematopoietic stem cells based on CART technology provided in an embodiment of the present invention;

[0070] Figure 2 This is a module diagram of a hematopoietic stem cell targeted delivery system based on CART technology provided in an embodiment of the present invention.

[0071] Figure 3 The comparison of the effects of the traditional method and the method of the present invention in maintaining the activity of CART cells is shown. The red curve represents the traditional method, and the blue curve represents the method of the present invention.

[0072] Figure 4 The comparison of the target recognition efficiency between the traditional method and the method of the present invention is demonstrated. DETAILED DESCRIPTION

[0073] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0074] like Figure 1 As shown, an embodiment of the present invention provides a method for targeted delivery of hematopoietic stem cells based on CART technology, and the method specifically includes:

[0075] S1: Targeted modification of CART cells. Through genetic engineering technology, CART cells are modified to express receptor proteins on their surface that specifically recognize hematopoietic stem cells, thereby achieving targeted recognition;

[0076] S2: Optimize the design of the delivery system and develop a nanocarrier or microsphere system to load the modified CART cells to improve their stability and delivery efficiency in the blood;

[0077] S3: Selection of biocompatible materials: Use materials with good biocompatibility as carriers to ensure that they do not cause immune responses in the body and can be safely degraded after completing the delivery task;

[0078] S4: In vivo tracking and monitoring, introducing technologies such as fluorescence or magnetic resonance imaging to monitor and evaluate the delivery path and targeting effect of CART cells in real time.

[0079] As a specific solution of the embodiment of the present invention, the specific implementation method of step S2 is:

[0080] S2: Optimal design of conveying system

[0081] This step involves developing a nanocarrier or microsphere system to improve the stability and delivery efficiency of the modified CART cells in the blood. The specific implementation method is as follows:

[0082] 1. Selection of nanocarrier or microsphere materials

[0083] Selecting the right material is a critical step in developing an effective delivery system. Common materials include:

[0084] Biodegradable polymers: such as PLGA (poly(lactic-co-glycolic acid)), which have good biocompatibility and degradability.

[0085] Lipid nanoparticles: such as liposomes, have good encapsulation ability and stability.

[0086] Inorganic nanoparticles: such as gold nanoparticles and magnetic nanoparticles, have unique physical and chemical properties that facilitate targeted and controlled release.

[0087] 2. Preparation of Nanocarriers or Microspheres

[0088] After selecting the material, the nanocarriers or microspheres are prepared by the following steps:

[0089] Solvent evaporation method: The polymer is dissolved in an organic solvent, the solution is then emulsified in an aqueous phase, and the organic solvent is evaporated to form nanoparticles.

[0090] Ultrasonic method: Ultrasonic energy is used to emulsify the polymer solution in the water phase to form uniform nanoparticles.

[0091] Double emulsion method: First, the drug and polymer are dissolved in an organic solvent to form colostrum, and then the colostrum is emulsified in an aqueous phase to form a double emulsion. Finally, the organic solvent is evaporated to form nanoparticles.

[0092] 3. Loading of CART cells

[0093] Loading modified CART cells into nanocarriers or microspheres to improve their stability and delivery efficiency in the blood:

[0094] Physical encapsulation: CART cells are directly mixed into the nanocarrier or microsphere preparation process so that they are physically encapsulated inside the carrier.

[0095] Chemical binding: Through surface modification technology, ligands that bind to specific receptor proteins on the surface of CART cells are introduced onto the surface of nanocarriers or microspheres to achieve stable loading of cells.

[0096] 4. Surface modification of carrier

[0097] Surface modification of nanocarriers or microspheres to further improve their stability and targeting:

[0098] Polyethylene glycol (PEG) modification: PEG modification can increase the blood circulation time of nanocarriers or microspheres and reduce the recognition and clearance by the immune system.

[0099] Targeting ligand modification: Targeting ligands, such as antibodies or small molecule ligands, are modified on the surface of the carrier to enhance its targeting recognition ability for hematopoietic stem cells.

[0100] 5. Performance evaluation

[0101] The prepared nanocarriers or microspheres are evaluated for performance, including:

[0102] Stability: The size and morphology of the nanoparticles were investigated by dynamic light scattering (DLS) and transmission electron microscopy (TEM).

[0103] Encapsulation efficiency and drug loading: The encapsulation efficiency and drug loading of the nanocarriers or microspheres were determined by high performance liquid chromatography (HPLC) or fluorescence spectrophotometer.

[0104] In vitro release behavior: The release behavior of CART cells in nanocarriers or microspheres was measured in a simulated body fluid environment.

[0105] Biocompatibility: The biocompatibility of nanocarriers or microspheres was evaluated by cell viability assays (such as MTT or CCK-8).

[0106] Through the above steps, the optimized design of the nanocarrier or microsphere system is achieved to ensure the stability and efficient delivery of the modified CART cells in the blood, thereby improving their ability to target hematopoietic stem cells.

[0107] The embodiment of the present invention provides a method for targeted delivery of hematopoietic stem cells based on CART technology, which aims to improve the stability and delivery efficiency of CART cells in the blood and ensure their safety and effectiveness in vivo. The working principle of this method includes four main steps: targeted modification of CART cells, optimized design of the delivery system, selection of biocompatible materials, and in vivo tracking and monitoring.

[0108] First, CART cells are modified through genetic engineering technology so that their surface expression can specifically recognize hematopoietic stem cells. The specific steps include determining the receptor protein specifically expressed on the surface of hematopoietic stem cells, using gene editing tools such as CRISPR / Cas9, TALENs or ZFN to genetically modify CART cells, and constructing expression vectors containing targeted receptor genes (such as adenovirus vectors or lentivirus vectors). The targeted receptor gene is introduced into CART cells by methods such as viral transfection, liposome transfection or electroporation, and finally, flow cytometry and fluorescence microscopy are used to screen and verify whether the transfected CART cells successfully express specific receptor proteins.

[0109] Secondly, develop a nanocarrier or microsphere system to load the modified CART cells into it to improve their stability and delivery efficiency in the blood. The nanocarrier or microsphere system can effectively protect CART cells from mechanical damage in the blood or recognition and removal by the immune system. The optimized design of this system ensures that CART cells can be efficiently and stably delivered to the target site by controlling the size, surface charge and material properties of nanoparticles or microspheres.

[0110] Third, select materials with good biocompatibility as carriers to ensure that they do not cause immune responses in the body and can be safely degraded after completing the delivery task. The selected materials should have excellent biocompatibility and degradability, such as polylactic acid-co-glycolic acid (PLGA). Through materials science and biomedical engineering technology, the physical and chemical properties of the carrier are optimized to ensure its safety and effectiveness in the body.

[0111] Fourth, introduce technologies such as fluorescence or magnetic resonance imaging to monitor and evaluate the delivery path and targeting effect of CART cells in real time. Fluorescence imaging technology uses fluorescent markers to mark CART cells and uses laser scanning confocal microscopy for imaging to achieve visual monitoring of the delivery path of CART cells in the body. Magnetic resonance imaging (MRI) technology uses magnetic nanoparticles to mark CART cells and perform imaging on MRI equipment to provide high-resolution three-dimensional imaging data to accurately evaluate the targeting effect of CART cells.

[0112] Fifth, comprehensively analyze the in vivo tracking and monitoring data, and evaluate the targeting effect and stability of CART cells in real time through the data analysis and feedback system. The data analysis system integrates and processes the data of fluorescence imaging and magnetic resonance imaging to generate a dynamic distribution map of CART cells in the body and a targeting effect evaluation report. Based on the analysis results, optimize the targeted transformation and delivery system design to ensure the continuous improvement and optimization of the treatment plan.

[0113] Finally, by optimizing the targeted transformation of CART cells, the design of the delivery system, the selection of biocompatible materials, and the in vivo tracking and monitoring technology, the present invention provides an efficient, safe, and accurate CART cell delivery method. This method significantly improves the application effect of CART cells in hematopoietic stem cell transplantation, provides patients with a more effective treatment plan, and promotes the development and clinical application of CART cell therapy technology.

[0114] The S1 comprises the following steps:

[0115] (1) Determination of target recognition receptors: First, identify the receptor proteins specifically expressed on the surface of hematopoietic stem cells. These receptors can be designed for targeted modification of CART cells.

[0116] (2) Selection of genetic engineering tools: Genetic modification of CART cells using gene editing tools such as CRISPR / Cas9, TALENs or ZFN.

[0117] (3) Vector construction: construct an expression vector containing the target receptor gene, such as adenovirus vector, lentivirus vector, etc.

[0118] (4) Gene transfection: The target receptor gene is introduced into CART cells through viral transfection, liposome transfection or electroporation.

[0119] (5) Screening and verification: The transfected CART cells are screened by flow cytometry, fluorescence microscopy, and other methods to verify whether they successfully express specific receptor proteins.

[0120] The S2 comprises the following steps:

[0121] (1) Selection of nanocarriers: Select appropriate nanocarriers, such as liposomes, polymer nanoparticles, gold nanoparticles, etc. These carriers need to have good biocompatibility and stability.

[0122] (2) Preparation of nanocarriers: Nanocarriers are prepared by emulsification-solvent evaporation, coprecipitation or ultrasound, and the modified CART cells are loaded therein.

[0123] (3) Surface modification: The surface of the nanocarrier is modified to enable it to have the functions of targeted recognition and long circulation. For example, surface modification with polyethylene glycol (PEG) can prolong its circulation time in the blood.

[0124] (4) Combination of carrier and CART cells: CART cells are fixed on the nanocarrier through physical adsorption or chemical bonding to form a stable complex.

[0125] (5) Stability test: The stability and delivery efficiency of the nanocarrier-CART cell complex were tested through in vitro and in vivo experiments.

[0126] The S3 comprises the following steps:

[0127] (1) Material screening: Select materials with good biocompatibility, such as polylactic acid-co-glycolic acid (PLGA), chitosan, hyaluronic acid, etc. These materials need to be FDA certified to ensure their safety in the body.

[0128] (2) Material preparation: Based on the characteristics of the selected material, the corresponding method is adopted for preparation, such as solvent evaporation method, freeze-drying method, etc.

[0129] (3) Biocompatibility testing: The biocompatibility and degradability of the material are verified through in vitro cytotoxicity experiments, in vivo biodegradation experiments, etc., to ensure that it can be safely metabolized or degraded in the body after completing the delivery task.

[0130] (4) Functional modification: introducing functional groups, such as antibodies and peptides, into the material to enhance its targeting and stability.

[0131] The S4 comprises the following steps:

[0132] (1) Selection of markers: Select markers suitable for in vivo imaging, such as fluorescent dyes (FITC, Rhodamine), magnetic nanoparticles (Fe3O4), etc.

[0133] (2) Binding of markers: The markers are bound to CART cells or nanocarriers through covalent bonding or physical adsorption to ensure that the markers do not fall off during the delivery process.

[0134] (3) Application of imaging technology: Fluorescence imaging, magnetic resonance imaging (MRI) and other technologies are used to track and monitor labeled CART cells in vivo.

[0135] (4) Data analysis: The imaging data is analyzed using image processing software to evaluate the delivery pathway, targeting efficiency, and retention time of CART cells at the target site.

[0136] (5) Feedback and optimization: Based on the monitoring results, adjustments and optimizations are made to the transformation of CART cells and the design of nanocarriers to further improve their targeted delivery effects.

[0137] like Figure 2 As shown, the hematopoietic stem cell targeted delivery system based on CART technology provided by the embodiment of the present invention includes:

[0138] Targeted transformation module, used to transform CART cells;

[0139] A carrier design module is used to develop nanocarrier or microsphere systems and load the modified CART cells into them;

[0140] The tracking and detection module uses fluorescence or magnetic resonance imaging technology to achieve in vivo tracking and monitoring of CART cells.

[0141] Example 1: CART cell targeted transformation and nanocarrier delivery system based on CRISPR / Cas9 technology

[0142] Background and Objectives

[0143] Through CRISPR / Cas9 gene editing technology, CART cells are targeted and modified to enable them to specifically recognize and target hematopoietic stem cells. Subsequently, a nanocarrier system is used to improve the stability and delivery efficiency of CART cells in the blood.

[0144] Implementation steps

[0145] Step 1: Identification of target recognition receptors

[0146] Through literature research and experimental analysis, the receptor proteins (such as CD34) specifically expressed on the surface of hematopoietic stem cells were determined.

[0147] Step 2: Selection of genetic engineering tools

[0148] The CRISPR / Cas9 system was selected as a gene editing tool, and gRNA was designed for CART cells so that they could express receptor proteins that recognize CD34.

[0149] Step 3: Vector construction

[0150] Adenoviral vectors were used to construct expression vectors containing the targeting receptor gene and the Cas9 gene.

[0151] Step 4: Gene transfection

[0152] The targeting receptor gene is introduced into CART cells through adenovirus transfection.

[0153] Step 5: Screening and Verification

[0154] Flow cytometry and fluorescence microscopy were used to screen the transfected CART cells to verify whether they successfully expressed the specific receptor protein CD34.

[0155] Step 6: Selection and preparation of nanocarriers

[0156] Polylactic acid-glycolic acid copolymer (PLGA) was selected as the nanocarrier, the nanocarrier was prepared by the emulsification-solvent evaporation method, and the modified CART cells were loaded into it.

[0157] Step 7: Surface modification

[0158] Polyethylene glycol (PEG) is modified on the surface of the nanocarrier to prolong its circulation time in the blood and enhance its targeting.

[0159] Step 8: Combination of vector and CART cells

[0160] Through physical adsorption, CART cells are fixed on the nanocarrier to form a stable complex.

[0161] Step 9: Stability Test

[0162] The stability and delivery efficiency of the nanocarrier-CART cell complex were tested through in vitro and in vivo experiments.

[0163] Step 10: In-body Tracking and Monitoring

[0164] Magnetic nanoparticles (Fe3O4) were selected as markers and combined with nanocarriers through covalent bonding.

[0165] Magnetic resonance imaging (MRI) technology was used to track and monitor the labeled CART cells in vivo to evaluate their delivery pathway and targeting efficiency.

[0166] Results and Analysis

[0167] The modified CART cells successfully expressed the specific receptor protein CD34.

[0168] The nanocarrier-CART cell complex has good stability and long circulation time in the blood.

[0169] In vivo tracking results showed that CART cells can efficiently target and deliver to the target site where hematopoietic stem cells are located.

[0170] Example 2: CART cell targeted modification and gold nanoparticle delivery system based on TALENs technology

[0171] Background and Objectives

[0172] TALENs gene editing technology is used to target and modify CART cells, enabling them to recognize and deliver targeted hematopoietic stem cells. At the same time, gold nanoparticles are used as a carrier system to enhance the stability and delivery efficiency of CART cells.

[0173] Implementation steps

[0174] Step 1: Identification of target recognition receptors

[0175] The receptor proteins (such as CXCR4) specifically expressed on the surface of hematopoietic stem cells are determined through experiments.

[0176] Step 2: Selection of genetic engineering tools

[0177] The TALENs system was selected as a gene editing tool, and TALENs were designed for CART cells so that they could express receptor proteins that recognize CXCR4.

[0178] Step 3: Vector construction

[0179] Lentiviral vectors were used to construct expression vectors containing the targeting receptor gene and TALENs gene.

[0180] Step 4: Gene transfection

[0181] The targeted receptor gene is introduced into CART cells through lentiviral transfection.

[0182] Step 5: Screening and Verification

[0183] The transfected CART cells were screened by flow cytometry and fluorescence microscopy to verify whether they successfully expressed the specific receptor protein CXCR4.

[0184] Step 6: Selection and preparation of nanocarriers

[0185] Gold nanoparticles were selected as nanocarriers, prepared by co-precipitation method, and the modified CART cells were loaded into them.

[0186] Step 7: Surface modification

[0187] Hyaluronic acid (HA) was modified on the surface of gold nanoparticles to improve their targeting and biocompatibility.

[0188] Step 8: Combination of vector and CART cells

[0189] CART cells are fixed on gold nanoparticles through chemical bonding to form a stable complex.

[0190] Step 9: Stability Test

[0191] The stability and delivery efficiency of the gold nanoparticle-CART cell complex were tested through in vitro and in vivo experiments.

[0192] Step 10: In-body Tracking and Monitoring

[0193] Fluorescent dye (Rhodamine) was selected as a marker and combined with gold nanoparticles through physical adsorption.

[0194] Fluorescence imaging technology is used to track and monitor the labeled CART cells in vivo to evaluate their delivery pathway and targeting efficiency.

[0195] Results and Analysis

[0196] The modified CART cells successfully expressed the specific receptor protein CXCR4.

[0197] The gold nanoparticle-CART cell complex has good stability and targeting in the blood.

[0198] In vivo tracking results showed that CART cells can efficiently target and deliver to the target site where hematopoietic stem cells are located.

[0199] The above two embodiments demonstrate the application of different gene editing tools and nanocarrier systems in the targeted modification and delivery of CART cells, which effectively improves the targeting and delivery efficiency of CART cells and provides a new technical means for hematopoietic stem cell transplantation therapy.

[0200] Comparison of CART cell activity maintenance effect: Figure 3 The comparison of the effects of the traditional method and the method of the present invention in maintaining the activity of CART cells is shown. The red curve represents the traditional method, and the blue curve represents the method of the present invention. The method of the present invention achieves long-term maintenance of the activity of CART cells after transplantation through targeted transformation and optimized design of the delivery system.

[0201] Comparison of targeted recognition efficiency: Figure 4 The comparison of the targeting recognition efficiency between the traditional method and the method of the present invention is shown. The green curve represents the traditional method, and the purple curve represents the method of the present invention. The method of the present invention improves the targeting recognition efficiency of CART cells to hematopoietic stem cells through genetic engineering technology and nanocarrier design.

[0202] These graphs clearly show that the present invention has achieved significant technological progress in maintaining CART cell activity and targeting recognition efficiency, and can provide more lasting and effective support for clinical treatment.

[0203] It should be noted that the embodiments of the present invention can be implemented by hardware, software, or a combination of software and hardware. The hardware part can be implemented using dedicated logic; the software part can be stored in a memory and executed by an appropriate instruction execution system, such as a microprocessor or dedicated design hardware. It can be understood by a person of ordinary skill in the art that the above-mentioned devices and methods can be implemented using computer executable instructions and / or contained in a processor control code, such as a carrier medium such as a disk, CD or DVD-ROM, a programmable memory such as a read-only memory (firmware), or a data carrier such as an optical or electronic signal carrier. Such code is provided on the carrier medium. The device and its modules of the present invention can be implemented by hardware circuits such as very large-scale integrated circuits or gate arrays, semiconductors such as logic chips, transistors, etc., or programmable hardware devices such as field programmable gate arrays, programmable logic devices, etc., can also be implemented by software executed by various types of processors, and can also be implemented by a combination of the above-mentioned hardware circuits and software, such as firmware.

[0204] The above description is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Any modifications, equivalent substitutions and improvements made by any technician familiar with the technical field within the technical scope disclosed by the present invention and within the spirit and principle of the present invention should be covered by the protection scope of the present invention.

Claims

1. An intelligent system for targeted delivery of hematopoietic stem cells based on CART technology, characterized in that: include: The targeted modification module is used to modify CART cells through genetic engineering technology so that they express receptor proteins that specifically recognize hematopoietic stem cells on their surface to achieve targeted recognition. It includes the following submodules: The target recognition receptor determination submodule is used to determine the receptor proteins specifically expressed on the surface of hematopoietic stem cells; Genetic engineering tool selection submodule, used to genetically modify CART cells using CRISPR / Cas9, TALENs or ZFN gene editing tools; A vector construction submodule, used to construct an expression vector containing a targeting receptor gene; A gene transfection submodule is used to introduce the target receptor gene into CART cells by viral transfection, liposome transfection or electroporation; The screening and verification submodule is used to screen the transfected CART cells by flow cytometry and fluorescence microscopy to verify whether they successfully express specific receptor proteins; The delivery system optimization design module is used to develop a nanocarrier or microsphere system to load the modified CART cells to improve their stability and delivery efficiency in the blood; A biocompatible material selection module is used to select materials with good biocompatibility as carriers to ensure that they will not cause immune responses in the body and can be safely degraded after completing the delivery task; In vivo tracking and monitoring module, which is used to introduce fluorescence or magnetic resonance imaging technology to monitor and evaluate the delivery path and targeting effect of CART cells in real time; The data analysis and feedback module is used to comprehensively analyze the in vivo tracking and monitoring data, evaluate the targeting effect of CART cells, and optimize the targeting modification and delivery system design based on the analysis results.

2. The intelligent system according to claim 1, wherein: The targeted transformation module further comprises: High-throughput screening submodule, which is used to quickly screen and identify receptor proteins specifically expressed on the surface of hematopoietic stem cells through high-throughput screening technology to ensure the accuracy and efficiency of targeted modification; The targeted receptor library construction submodule is used to construct a targeted receptor gene library, which contains a variety of receptor gene sequences, so as to select the receptor gene most suitable for CART cell targeted modification; The targeted receptor expression optimization submodule is used to optimize the expression level of the targeted receptor in CART cells and achieve efficient expression of the targeted receptor by regulating the promoter and other regulatory elements of the expression vector.

3. The intelligent system according to claim 1, wherein: The conveying system optimization design module further includes: Nanocarrier design submodule, which is used to design and optimize nanocarriers for CART cell delivery to ensure their high stability and efficient delivery in the blood; The microsphere system design submodule is used to develop a microsphere system for CART cell delivery to ensure that it can effectively encapsulate CART cells and release them in vivo to provide a lasting therapeutic effect; The delivery efficiency evaluation submodule is used to evaluate the delivery efficiency of nanocarriers and microsphere systems through in vitro experiments and in vivo models, and optimize design parameters to improve the delivery effect.

4. The intelligent system according to claim 1, wherein: The in vivo tracking and monitoring module further comprises: Fluorescence imaging submodule, which uses fluorescence labeling technology to monitor the delivery path and distribution of CART cells in the body in real time and provide high-resolution imaging data; The magnetic resonance imaging submodule is used to non-invasively monitor the location and targeting effect of CART cells in the body through magnetic resonance imaging technology to ensure the safety and effectiveness of the treatment process; The data integration and analysis submodule is used to integrate fluorescence imaging and magnetic resonance imaging data, combine in vivo and in vitro experimental results, conduct comprehensive analysis and evaluation of the targeted delivery effect of CART cells, and provide optimization suggestions.

5. The intelligent system according to claim 1, wherein: The optimized design of the delivery system in the hematopoietic stem cell targeted delivery method based on CART technology includes the following steps: a. The nanocarrier or microsphere system used is made of biocompatible materials and can be loaded with CART cells modified by genetic engineering technology; b. surface modification of the nanocarrier or microsphere system to increase its stability and compatibility in the blood; c. loading the modified CART cells into the nanocarrier or microsphere system to form a CART cell loading system; d. By adjusting the physical and chemical properties of the CART cell loading system, its delivery efficiency in the blood is optimized to ensure that the CART cells can efficiently and stably reach the target hematopoietic stem cells; e. Deliver the CART cell loading system into the patient through an appropriate route to achieve targeted delivery of hematopoietic stem cells.

6. A method for targeted delivery of hematopoietic stem cells based on CART technology, characterized in that: The method specifically includes: S1: Targeted modification of CART cells. Through genetic engineering technology, CART cells are modified to express receptor proteins on their surface that specifically recognize hematopoietic stem cells, thereby achieving targeted recognition; S2: Optimization design of the delivery system, developing a nanocarrier or microsphere system to load the modified CART cells to improve their stability and delivery efficiency in the blood; S3: Selection of biocompatible materials: Use materials with good biocompatibility as carriers to ensure that they do not cause immune responses in the body and can be safely degraded after completing the delivery task; S4: In vivo tracking and monitoring, introducing fluorescence or magnetic resonance imaging technology to monitor and evaluate the delivery path and targeting effect of CART cells in real time.

7. The method for targeted delivery of hematopoietic stem cells based on CART technology as claimed in claim 6, characterized in that: The S1 comprises the following steps: (1) Determination of target recognition receptors: First, determine the receptor proteins specifically expressed on the surface of hematopoietic stem cells. These receptors can be designed for targeted modification of CART cells; (2) Selection of genetic engineering tools: Genetically modify CART cells using CRISPR / Cas9, TALENs or ZFN gene editing tools; (3) Vector construction: constructing an expression vector containing the target receptor gene, such as an adenovirus vector or a lentivirus vector; (4) Gene transfection: The targeted receptor gene is introduced into CART cells by viral transfection, liposome transfection or electroporation; (5) Screening and verification: The transfected CART cells are screened by flow cytometry and fluorescence microscopy to verify whether they successfully express specific receptor proteins.

8. The method for targeted delivery of hematopoietic stem cells based on CART technology as claimed in claim 6, characterized in that: The S2 comprises the following steps: (1) Selection of nanocarriers: Select appropriate nanocarriers, such as liposomes, polymer nanoparticles, and gold nanoparticles. These carriers need to have good biocompatibility and stability. (2) Preparation of nanocarriers: Prepare nanocarriers by emulsification-solvent evaporation method, coprecipitation method or ultrasound method, and load the modified CART cells into them; (3) Surface modification: The surface of the nanocarrier is modified to enable it to have the functions of targeted recognition and long circulation. For example, surface modification with polyethylene glycol (PEG) can prolong its circulation time in the blood. (4) Binding of carrier and CART cells: CART cells are fixed on the nanocarrier by physical adsorption or chemical bonding to form a stable complex; (5) Stability test: The stability and delivery efficiency of the nanocarrier-CART cell complex were tested through in vitro and in vivo experiments.

9. The method for targeted delivery of hematopoietic stem cells based on CART technology as claimed in claim 6, characterized in that: The S3 comprises the following steps: (1) Material screening: Select materials with good biocompatibility, including poly(lactic-co-glycolic acid) (PLGA), chitosan, and hyaluronic acid; (2) Material preparation: Based on the characteristics of the selected material, the corresponding method is used for preparation, such as solvent evaporation method and freeze-drying method; (3) Biocompatibility testing: Verify the biocompatibility and degradability of the material through in vitro cytotoxicity tests and in vivo biodegradation tests to ensure that it can be safely metabolized or degraded in the body after completing the delivery task; (4) Functional modification: introducing functional groups, such as antibodies and peptides, into the material to enhance its targeting and stability.

10. The method for targeted delivery of hematopoietic stem cells based on CART technology as claimed in claim 6, characterized in that: The S4 comprises the following steps: (1) Selection of markers: Select markers suitable for in vivo imaging, such as fluorescent dyes (FITC, Rhodamine) and magnetic nanoparticles (Fe3O4); (2) Binding of markers: The markers are bound to CART cells or nanocarriers by covalent bonding or physical adsorption to ensure that the markers do not fall off during delivery; (3) Application of imaging technology: Fluorescence imaging and magnetic resonance imaging (MRI) technology are used to track and monitor labeled CART cells in vivo; (4) Data analysis: Analyze imaging data using image processing software to evaluate the delivery pathway, targeting efficiency, and retention time of CART cells at the target site; (5) Feedback and optimization: Based on the monitoring results, the modification of CART cells and the design of nanocarriers are adjusted and optimized to further improve their targeted delivery effect.